Mesoporous nanoparticles for the delivery of (9S, E)-8-ethyl-9-methylnonadec-6-en-3-one (EME): A study of anti-inflammatory and tumor suppressing potential in RAW 264.7, He La and HepG2 cell lines

Marine natural bioactive compounds have chemical diversities, which can be used to develop new potent drugs for various diseases. In this study, Lyngbya sp. (cyanobacterium), was used to explore for its biological potential against inflammation and cancer. (9S,E)-8-ethyl-9-methylnonadec-6-en-3-one (EME), was extracted from Lyngbya sp., purified, and characterized by different spectroscopic techniques. In addition, EME was assessed for the antiinflammatory potential by Fluorescence Activated Cell Sorting Analysis (FACS) in Lipopolysaccharide (LPS) induced RAW 264.7 macrophage cell lines, and a significant reduction in COX-2 expression was observed. Further, COX-2, TNF-alpha, iNOS, NF-kappa beta, and IL-1 beta gene expressions were also analysed in EME treated LPS induced RAW 264.7 cell line by semi-quantitative PCR. Subsequently, to enhance the availability of EME into the cells for the anti-inflammatory potential, it was blended with aminated mesoporous silica nanoparticles (MSNPs). The expressions of COX-2, TNF-alpha, iNOS, NF-kappa beta, and IL-1 beta were significantly downregulated in EME + MSNPs treated LPS induced RAW 264.7 cells. Conclusively, EME combined with MSNPs showed the therapeutic potential of an antiinflammatory agent. Furthermore, the cytotoxic activity of EME was also explored in cervical (HeLa) and liver cancer (HepG2) cell lines; the western blotting results witnessed that EME had induced the expressions of p53, caspase-3, and p21.